Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganaxolone in TSC-related epilepsy
NCT05604170Phase 3Terminated
- Sponsor
- Marinus Pharmaceuticals
- Start
- May 2022
- Primary completion
- Apr 2025
- Modality
- Allosteric Modulators
- Countries
- 10
01
Overview
A Phase 3 trial of ganaxolone in epilepsy, sponsored by Marinus Pharmaceuticals. Started May 2022; status: terminated.
02
Drugs
ganaxolone
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT05604170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05604170.